Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation-Reference-Cited by-同舟云学术

Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation

Published:2017-12-01 Issue:1 Volume:32 Page:e13150
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Kalra Amit¹^ORCID,Roessner Cameron²,Jupp Jennifer²,Williamson Tyler¹,Tellier Raymond¹,Chaudhry Ahsan¹,Khan Faisal¹,Taparia Minakshi³,Jimenez-Zepeda Victor H.¹,Stewart Douglas A.¹³,Daly Andrew¹,Storek Jan¹

Affiliation:

1. University of Calgary; Calgary AB Canada

2. Pharmacy Services; Alberta Health Services; Calgary AB Canada

3. University of Alberta Edmonton; AB Canada

Funder

Alberta Innovates - Health Solutions

Alberta Cancer Foundation

Buckley Foundation

Publisher

Wiley

Subject

Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ctr.13150/fullpdf

Reference34 articles.

1. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study;Curtis;Blood,1999

2. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab;Patriarca;Transpl Infect Dis,2013

3. Identifying the patient at risk for post-transplant lymphoproliferative disorder;Cockfield;Transpl Infect Dis,2001

4. Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation;Styczynski;Clin Infect Dis,2013

5. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation;Landgren;Blood,2009

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Co-transplantation of umbilical cord mesenchymal stem cells and peripheral blood stem cells in children and adolescents with refractory or relapsed severe aplastic anemia;Pediatric Hematology and Oncology;2024-03-04

2. Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation;Bone Marrow Transplantation;2024-02-10

3. Infection Control, Prophylaxis, and Vaccinations in Hematopoietic Cell Transplantation Recipients;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

4. Rituximab for posttransplant lymphoproliferative disorder – therapeutic, preemptive, or prophylactic?;Bone Marrow Transplantation;2023-11-25

5. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy;Bone Marrow Transplantation;2023-10-21